Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment
(MedPage Today) -- Intratumoral infusion of an oncolytic virus offered safe and feasible results, along with encouraging efficacy, in pediatric patients with diffuse intrinsic pontine glioma (DIPG), researchers reported.
In the phase I study of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 29, 2022 Category: Hematology Source Type: news
Machine learning, radiomics differentiates glioma
An automated method based on a machine-learning algorithm and MRI radiomic...Read more on AuntMinnie.comRelated Reading:
SIIM: Neck pain in the radiology reading room? Consider the 'Han Solo' approach
SIIM: AI can detect multiple myeloma lesions on whole-body CT
Deep learning classifies brain tumors on single MRI scans
MRI, histopathologic features boost glioma survival prediction accuracy
AI can identify sarcopenia in glioblastoma patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 28, 2022 Category: Radiology Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Targeted Combo Topples Chemo in Pediatric Glioma With BRAF Mutations
(MedPage Today) -- CHICAGO -- Dual targeted therapy with a BRAF and MEK inhibitor quadrupled responses in pediatric BRAF-mutant low-grade glioma and reduced risk of disease progression or death compared with standard chemotherapy, a phase II... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news
Targeted Therapy an'Important Advance' in Childhood Glioma Targeted Therapy an'Important Advance' in Childhood Glioma
Combining dabrafenib with trametinib markedly improved response rates and delayed progression over standard-of-care chemotherapy in pediatric BRAF V600-mutant low-grade glioma in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Imaging Biometrics seeks FDA clearance for IB Zero G
Advanced visualization software developer Imaging Biometrics has submitted ...Read more on AuntMinnie.comRelated Reading:
Imaging Biometrics highlights findings on MRI-based glioma monitoring
Imaging Biometrics lands software install at Ala. medical center
Imaging Biometrics secures patent for zero-dose imaging software
Imaging Biometrics wins USC installation
Imaging Biometrics added to Arterys marketplace (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 31, 2022 Category: Radiology Source Type: news
The Potential of Nanopore Sequencing Technology in Cancer Diagnosis
In this webinar, Mashiat Mimosa will discuss the potential of a new sequencing method that detects glioma tumors in brain tissue. (Source: The Scientist)
Source: The Scientist - May 11, 2022 Category: Science Tags: Sponsored Webinars Source Type: news
Blood Biomarkers May Help ID Primary CNS Lymphoma, High - Grade Glioma
Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high - grade glioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 18, 2022 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Journal, Source Type: news
Blood Biomarkers May Help ID Primary CNS Lymphoma, High-Grade Glioma
MONDAY, April 18, 2022 -- Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2022 Category: Pharmaceuticals Source Type: news
Assay-Guided Chemo in Recurrent Glioma Linked to Longer Survival Assay-Guided Chemo in Recurrent Glioma Linked to Longer Survival
A new assay can help guide chemotherapy treatments for recurrent high-grade gliomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Imaging Biometrics highlights findings on MRI-based glioma monitoring
Advanced visualization software firm Imaging Biometrics is highlighting researc...Read more on AuntMinnie.comRelated Reading:
Imaging Biometrics lands software install at Ala. medical center
Imaging Biometrics secures patent for zero-dose imaging software
IB, Mayo Clinic partner to track brain lesions
Imaging Biometrics wins USC installation
Imaging Biometrics added to Arterys marketplace (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 7, 2022 Category: Radiology Source Type: news
What Is the Survival Rate of Glioma?
Title: What Is the Survival Rate of Glioma?Category: Diseases and ConditionsCreated: 2/16/2022 12:00:00 AMLast Editorial Review: 2/16/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2022 Category: Cancer & Oncology Source Type: news
Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor. (Source: World Pharma News)
Source: World Pharma News - November 25, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
Funds to support first-in-human (FIH) clinical trial of the company's proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas
OAKDALE, Minn., Nov. 17, 2021 -- (Healthcare Sales & Marketing Network) -- Alpheus ... Devices, Oncology, Venture Capital Alpheus Medical, sonodynamic therapy, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2021 Category: Pharmaceuticals Source Type: news
Dual-drug treatment offers hope to children with rare brain cancer
Scientists make ‘promising’ breakthrough on fast-growing DIPG type of tumourScientists have successfully combined two existing cancer drugs to create a treatment for children diagnosed with deadly brain tumours.Diffuse intrinsic pontine glioma (DIPG), a rare and fast-growing type of brain tumour in children, can mutate and evolve to resist treatment with a single drug. There is currently no cure and many children found to have the disease die within months.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 5, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Medical research Cancer Children's health UK news Science Source Type: news
